A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
A phase 2 trial of VS-7375, Cetuximab in pancreatic ductal adenocarcinoma, run by Verastem, Inc., now recruiting.
Overview
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer is a phase 2 interventional study registered as NCT07644559 by Verastem, Inc., with 180 participants planned, started 2026-06-16 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS. No results are recorded here; the registry entry is the source.
Setting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Phase
Phase 2
Sponsor
Verastem, Inc.
Registry
Enrolled
180
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Shares VS-7375, Verastem Oncology.
- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Shares VS-7375, Verastem Oncology, Cetuximab.
- TrialA Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Shares VS-7375, Verastem Oncology, Cetuximab, Pancreatic ductal adenocarcinoma.
- PersonVolker Heinemann
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- TrialStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)